The cardiovascular effects of two new triazine antimalarials, BRL 50216 (Clociguanil) and BRL 6231.
D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology; D000962:Antimalarials / Q000494:pharmacology*; D001593:Benzyl Compounds / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D002339:Carotid Arteries / Q000187:drug effects; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004562:Electrocardiography; D004987:Ethers / Q000494:pharmacology; D005263:Femoral Artery / Q000187:drug effects; D005268:Femoral Vein / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006632:Histamine / Q000494:pharmacology; D007545:Isoproterenol / Q000494:pharmacology; D009541:Nictitating Membrane / Q000187:drug effects; D009638:Norepinephrine / Q000494:pharmacology; D010646:Phentolamine / Q000494:pharmacology; D012110:Reserpine / Q000494:pharmacology; D012119:Respiration / Q000187:drug effects; D014227:Triazines / Q000494:pharmacology*; D014630:Vagus Nerve / Q000502:physiology; D014655:Vascular Resistance / Q000187:drug effects
D000889:Anti-Arrhythmia Agents; D000962:Antimalarials; D001593:Benzyl Compounds; D004987:Ethers; D014227:Triazines; C007087:clociguanil; C006201:BRL 6231; D006632:Histamine; D012110:Reserpine; D007545:Isoproterenol; D000109:Acetylcholine; D009638:Norepinephrine; D010646:Phentolamine